Abata Therapeutics develops regulatory T cell (Treg) therapies for treating autoimmune diseases including progressive multiple sclerosis.
Abata Therapeutics's investors include Lightspeed Venture Partners, Samsara BioCapital, Invus, Bristol-Myers Squibb, Third Rock Ventures.
Abata Therapeutics is headquartered in Cambridge, United States.
Abata Therapeutics develops regulatory T cell (Treg) therapies for treating autoimmune diseases including progressive multiple sclerosis.
Abata Therapeutics is at the Corporate Round stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Abata Therapeutics — Funding & Investors." VCBacked, August 15, 2024, https://www.vcbacked.co/company/abata-therapeutics. Accessed September 29, 2026.
VCBacked. (2024). Abata Therapeutics — Funding & Investors. Retrieved September 29, 2026, from https://www.vcbacked.co/company/abata-therapeutics
{{cite web |title=Abata Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/abata-therapeutics |website=VCBacked |access-date=September 29, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated